AU3456099A - Methods and compositions for eliciting an immune response to a telomerase antigen - Google Patents

Methods and compositions for eliciting an immune response to a telomerase antigen

Info

Publication number
AU3456099A
AU3456099A AU34560/99A AU3456099A AU3456099A AU 3456099 A AU3456099 A AU 3456099A AU 34560/99 A AU34560/99 A AU 34560/99A AU 3456099 A AU3456099 A AU 3456099A AU 3456099 A AU3456099 A AU 3456099A
Authority
AU
Australia
Prior art keywords
eliciting
compositions
methods
immune response
telomerase antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU34560/99A
Other languages
English (en)
Inventor
Federico C.A. Gaeta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geron Corp
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of AU3456099A publication Critical patent/AU3456099A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4246—Telomerase or [telomerase reverse transcriptase [TERT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU34560/99A 1998-03-31 1999-03-30 Methods and compositions for eliciting an immune response to a telomerase antigen Abandoned AU3456099A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11200698P 1998-03-31 1998-03-31
US60112006 1998-03-31
PCT/US1999/006898 WO1999050392A1 (en) 1998-03-31 1999-03-30 Methods and compositions for eliciting an immune response to a telomerase antigen

Publications (1)

Publication Number Publication Date
AU3456099A true AU3456099A (en) 1999-10-18

Family

ID=22341634

Family Applications (1)

Application Number Title Priority Date Filing Date
AU34560/99A Abandoned AU3456099A (en) 1998-03-31 1999-03-30 Methods and compositions for eliciting an immune response to a telomerase antigen

Country Status (6)

Country Link
US (1) US6440735B1 (enExample)
EP (1) EP1068296B1 (enExample)
JP (3) JP2002509716A (enExample)
AU (1) AU3456099A (enExample)
CA (1) CA2347067C (enExample)
WO (1) WO1999050392A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU781376B2 (en) * 1999-04-09 2005-05-19 Biomira Inc. Telomerase-specific cancer vaccine

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6808880B2 (en) * 1996-10-01 2004-10-26 Geron Corporation Method for detecting polynucleotides encoding telomerase
EA199900355A1 (ru) 1996-10-01 2000-08-28 Джерон Корпорейшн Теломераза обратная тринскриптаза
US6475789B1 (en) * 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
US6093809A (en) * 1996-10-01 2000-07-25 University Technology Corporation Telomerase
US6261836B1 (en) * 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) * 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US20050013825A1 (en) * 1997-04-18 2005-01-20 Geron Corporation Vaccine containing the catalytic subunit of telomerase for treating cancer
US7413864B2 (en) * 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
US7622549B2 (en) * 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
US6337200B1 (en) * 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
AU3456099A (en) 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
US7030211B1 (en) 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
US20020142974A1 (en) * 1998-09-11 2002-10-03 Leonard D. Kohn Immune activation by double-stranded polynucleotides
EP1126872B1 (en) * 1998-10-29 2006-12-13 Dana-Farber Cancer Institute, Inc. CANCER IMMUNOTHERAPY AND DIAGNOSIS USING UNIVERSAL TUMOR ASSOCIATED ANTIGENS, INCLUDING hTERT
AU2001241533A1 (en) 2000-02-15 2001-08-27 The Regents Of The University Of California A universal vaccine and method for treating cancer employing telomerase reverse transcriptase
EP1257284A4 (en) * 2000-02-15 2005-12-21 Univ California UNIVERSAL VACCINE AND METHOD OF TREATING CANCER USING TELOMERASE REVERSE TRANSCRIPTASE
GB0031430D0 (en) * 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
ATE552843T1 (de) * 2003-02-06 2012-04-15 Aduro Biotech Listerien deren eindringen in nicht-phagozytische zellen abgeschwächt ist, impfstoffe, die diese listerien enthalten und deren verwendungen
KR101173871B1 (ko) * 2003-02-06 2012-08-16 앤저 테라퓨틱스 인코퍼레이티드 변형된 독립생존 미생물, 백신 조성물 및 그것의 사용방법
US7695725B2 (en) * 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
CA2574802A1 (en) 2004-07-20 2006-02-02 Isogenis, Inc. Specific inhibition of autoimmunity and diseases associated with autoantigens
CA2504451A1 (en) * 2004-08-10 2006-02-10 Geron Corporation Dendritic cell vaccines for treating cancer made from embryonic stem cells
EP1801230A4 (en) * 2004-09-03 2008-03-05 Medical & Biol Lab Co Ltd METHOD FOR SELECTING LIGHT AS AN ANTIGEN PROTEINS PRESENTED ON DENTRIC CELLS
EP1801202A4 (en) * 2004-09-03 2008-02-06 Medical & Biol Lab Co Ltd METHOD FOR PRODUCING A DENDRITIC CELL WITH ACQUIRED CTL-INDUCING SKILL
US20090196850A1 (en) 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
EP1748067A1 (en) * 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
RU2309753C1 (ru) * 2006-05-05 2007-11-10 ЗАО "РеМеТэкс" Комбинированный клеточный трансплантат на основе лимфокинактивированных киллеров и дендритных клеток, способ его получения и способ лечения и профилактики онкологических, инфекционных заболеваний и иммунодефицитных состояний
PL2081595T3 (pl) 2006-09-26 2019-11-29 Genmab As Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
WO2010096693A2 (en) * 2009-02-19 2010-08-26 Mayo Foundation For Medical Education And Research Methods and materials for generating t cells
US8563307B2 (en) 2009-02-24 2013-10-22 James Wang Treatment of immunosuppression-related disorders
RU2581800C2 (ru) 2010-02-16 2016-04-20 Ультимовакс Ас Полипептиды
EP3904391B1 (en) 2010-03-10 2024-07-10 Genmab A/S Monoclonal antibodies against c-met
NZ604007A (en) 2010-05-27 2015-03-27 Genmab As Monoclonal antibodies against her2 epitope
IL299365A (en) 2010-05-27 2023-02-01 Genmab As Monoclonal antibodies against 2HER
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
JP6055404B2 (ja) 2010-06-15 2016-12-27 ゲンマブ エー／エス 組織因子に対するヒト抗体薬物結合体
US8679474B2 (en) 2010-08-04 2014-03-25 StemBios Technologies, Inc. Somatic stem cells
CA2832387A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecifc antibodies against her2
WO2012143524A2 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
EP2699260B1 (en) 2011-04-20 2024-11-20 Genmab A/S Bispecifc antibodies against her2
TWI614340B (zh) 2011-09-28 2018-02-11 幹細胞生物科技股份有限公司 體幹細胞及其製備方法
CN104822827B (zh) 2012-12-06 2020-01-21 干细胞生物科技公司 Lgr5+体干细胞
EP2746769A1 (en) 2012-12-21 2014-06-25 Stembios Technologies, Inc. Method for evaluating effect of action on subject based on stem celldynamics
US20170058043A1 (en) 2014-12-06 2017-03-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibody for cancer immunotherapy
CN107660214B (zh) 2015-01-08 2022-02-08 根马布股份公司 针对cd3和cd20的双特异性抗体
US11020465B2 (en) 2016-03-04 2021-06-01 The Trustees Of Columbia University In The City Of New York Development of dual whole cell-based vaccine against pancreatic cancer
AU2017305396A1 (en) * 2016-08-02 2019-02-21 Nant Holdings Ip, Llc Transfection of dendritic cells and methods therefor
AU2017336088B2 (en) * 2016-09-30 2023-07-06 Inovio Pharmaceuticals, Inc. Tert immunogenic compositions and methods of treatment using the same
EP3585403A4 (en) 2017-02-22 2020-12-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. CHEMERICAL ANTIGENIC RECEPTORS BINDING TO TIM3
CN111212663A (zh) 2017-07-07 2020-05-29 H·李·莫菲特癌症中心研究所公司 具有突变的cd28共刺激性结构域的嵌合抗原受体
US12036273B2 (en) 2018-01-08 2024-07-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Compositions and methods for targeting CD99-expressing cancers
US11951129B2 (en) 2018-01-09 2024-04-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Compositions and methods for targeting CLEC12A-expressing cancers
WO2020023361A1 (en) 2018-07-23 2020-01-30 H. Lee Moffitt Cancer Center And Research Institute Inc. Enhancing anti-tumor response in melanoma cells with defective sting signaling
KR20220110243A (ko) 2019-12-02 2022-08-05 셀진 코포레이션 암의 치료를 위한 요법
EP4110319B1 (en) 2020-02-27 2026-01-07 H. Lee Moffitt Cancer Center & Research Institute, Inc. Tumor-infiltrating lymphocytes with enhanced tumor reactivity
WO2021226063A1 (en) 2020-05-05 2021-11-11 Regeneron Pharmaceuticals, Inc. Car comprising cd28 zeta and cd3 zeta
WO2024206155A1 (en) 2023-03-24 2024-10-03 Cornell University Utilizing t cells derived from tumor draining lymph nodes for chimeric antigen receptor (car) t cell therapy for the treatment of cancer

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3483252D1 (de) 1983-12-05 1990-10-25 Asahi Chemical Ind Verfahren zur induktion von antitumorimmunozyten, verfahren zur herstellung von antitumorimmunozyten und durch das verfahren hergestellte antitumorimmunozyten.
US6004807A (en) 1992-03-30 1999-12-21 Schering Corporation In vitro generation of human dendritic cells
PT633929E (pt) 1992-04-01 2004-07-30 Merix Bioscience Inc Metodo para proliferacao (in vitro) de precursores de celulas dentifricas e sua utilizacao para produzir imunogenios
AU687733B2 (en) 1992-04-01 1998-03-05 Rockefeller University, The Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
IL105503A (en) 1992-04-28 1999-05-09 Astra Ab Carbon peptide couplets capable of eliciting an immune response of T cells
US5648215A (en) 1992-05-13 1997-07-15 Board Of Regents, The University Of Texas System Telomerase diagnostic methods
US5629154A (en) 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5639613A (en) 1992-05-13 1997-06-17 Board Of Regents, University Of Texas System Methods for cancer diagnosis and prognosis
US5645986A (en) * 1992-05-13 1997-07-08 Board Of Reagents, The University Of Texas System Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
WO1994002156A1 (en) * 1992-07-16 1994-02-03 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate t cells
US6077519A (en) 1993-01-29 2000-06-20 University Of Pittsburgh Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
CA2158281A1 (en) 1993-03-15 1994-09-29 Jay A. Berzofsky Peptide coated dendritic cells as immunogens
KR960701988A (ko) * 1993-04-20 1996-03-28 윌리엄 에스. 로빈슨 세포내 감염원에 감염된 개체의 치료방법 및 치료물질(methods and materials for treatment of individuals infected with intracellular in-fectious agents)
IT1264516B1 (it) 1993-05-31 1996-09-24 Biotop Sas Di Rita Cassarin Cellule dendritiche immortalizzate
DE4412794A1 (de) 1994-04-14 1995-12-14 Univ Ludwigs Albert Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
DK0765386T3 (en) 1994-06-14 2015-01-26 Univ Leland Stanford Junior Methods for T cell activation in vivo with antigen-incubated dendritic cells
US5972627A (en) 1994-06-15 1999-10-26 Systemix, Inc. Method of purifying a population of cells enriched for dendritic and/or lymphoid progenitors and populations of cells obtained thereby
JP3680219B2 (ja) 1994-06-28 2005-08-10 独立行政法人理化学研究所 癌細胞障害性ｔリンパ球の誘導培養方法
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5648219A (en) 1995-06-07 1997-07-15 Zymogenetics, Inc. Immortalized dendritic cells
US5643786A (en) 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
US6010905A (en) 1995-01-27 2000-01-04 The United States Of America As Represented By The Department Of Health & Human Services Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells
US5871728A (en) 1995-03-31 1999-02-16 University Of Pittsburgh Method of regulating dendritic cell maturation
US5656638A (en) * 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US6015554A (en) 1995-06-07 2000-01-18 Systemix, Inc. Method of reconstituting human lymphoid and dendritic cells
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US5968506A (en) * 1995-08-04 1999-10-19 Geron Corporation Purified telomerase
AU7152296A (en) 1995-08-16 1997-03-12 Board Of Trustees Of The Leland Stanford Junior University Adult oligodendrocyte precursor cell compositions and methods
US5858777A (en) 1995-09-08 1999-01-12 Geron Corporation Methods and reagents for regulating telomere length and telomerase activity
WO1997022349A1 (en) 1995-12-20 1997-06-26 The Board Of Trustees Of The Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
US6080409A (en) 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
US6224870B1 (en) * 1997-01-24 2001-05-01 Genitrix, Ltd. Vaccine compositions and methods of modulating immune responses
JP2000505650A (ja) 1996-02-08 2000-05-16 アメリカ合衆国 樹状突起細胞を形質転換し、そしてｔ細胞を活性化するための方法及び組成物
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
EP0906444A1 (de) 1996-04-19 1999-04-07 Gabriele Pecher Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US5770422A (en) 1996-07-08 1998-06-23 The Regents Of The University Of California Human telomerase
US5747317A (en) 1996-07-08 1998-05-05 Tularik Inc. Human telomerase RNA interacting protein gene
US6017527A (en) 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
KR20000022445A (ko) 1996-07-10 2000-04-25 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 수상돌기 세포의 활성화 방법
WO1998007838A1 (en) 1996-08-21 1998-02-26 Mitsubishi Chemical Corporation Higher animal telomerase protein and gene encoding the same
EA199900355A1 (ru) 1996-10-01 2000-08-28 Джерон Корпорейшн Теломераза обратная тринскриптаза
US6093809A (en) 1996-10-01 2000-07-25 University Technology Corporation Telomerase
CH689672A9 (de) 1996-10-01 2000-02-29 Geron Corp Katalytische Untereinheit menschlicher Telomerase.
US6261836B1 (en) * 1996-10-01 2001-07-17 Geron Corporation Telomerase
US5812477A (en) 1996-10-03 1998-09-22 Micron Technology, Inc. Antifuse detection circuit
US6008004A (en) 1996-10-04 1999-12-28 Becton Dickinson & Company Identification of a CD34+ bone marrow precursor for dendritic cells in blood and lymphoid tissues
EP0931138A4 (en) 1996-10-10 2003-04-09 Univ Duke METHOD FOR PRODUCING A THYMIC MICRO ENVIRONMENT TO SUPPORT DENDRITIC CELL DEVELOPMENT
US7390891B1 (en) 1996-11-15 2008-06-24 Amgen Inc. Polynucleotides encoding a telomerase component TP2
US5962318A (en) 1996-11-15 1999-10-05 St. Jude Children's Research Hospital Cytotoxic T lymphocyte-mediated immunotherapy
US5919656A (en) 1996-11-15 1999-07-06 Amgen Canada Inc. Genes encoding telomerase protein 1
WO1998023759A2 (en) 1996-11-26 1998-06-04 Baylor College Of Medicine Identification of inhibitors that prevent access of telomerase to chromosomal terminus
WO1998037181A2 (en) 1997-02-20 1998-08-27 Whitehead Institute For Biomedical Research Telomerase catalytic subunit gene and encoded protein
WO1998046083A1 (en) 1997-04-17 1998-10-22 The Regents Of The University Of California Use of lentiviral vectors for antigen presentation in dendritic cells
AUPO723097A0 (en) 1997-06-06 1997-07-03 Australian National University, The A method for culturing cells
AU745420B2 (en) 1997-06-20 2002-03-21 Bayer Aktiengesellschaft Human catalytic telomerase sub-unit and its diagnostic and therapeutic use
US6288303B1 (en) 1997-06-25 2001-09-11 The Regents Of The University Of California Rice β-glucanase enzymes and genes
KR100581990B1 (ko) 1997-07-01 2006-05-23 캄비아 바이오시스템즈 엘엘씨 척추 동물 텔로머라제 유전자 및 단백질과 이의 용도
AU1220599A (en) 1997-11-14 1999-06-07 Hemosol Inc. Method for the production and use of dendritic cells
AU3456099A (en) 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
AU3549499A (en) 1998-04-06 1999-10-25 Johns Hopkins University School Of Medicine, The Telomerase-associated proteins
EP1082411A2 (en) 1998-06-02 2001-03-14 Dendreon Corporation Method for preparation and in vivo administration of antigen presenting cell composition
US6277613B1 (en) 1998-06-10 2001-08-21 The Rockefeller University TRF1 binding protein, methods of use thereof
WO1999063945A2 (en) 1998-06-12 1999-12-16 Sloan-Kettering Institute For Cancer Research Vaccination strategy to prevent and treat cancers
US7030211B1 (en) 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
GB9816781D0 (en) 1998-07-31 1998-09-30 Univ London Herpes virus vectors for dendritic cells
JP4768916B2 (ja) 1998-09-15 2011-09-07 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション サイトカイン発現が遺伝的に増強された抗原提示細胞のインサイチュ注入
EP1126872B1 (en) 1998-10-29 2006-12-13 Dana-Farber Cancer Institute, Inc. CANCER IMMUNOTHERAPY AND DIAGNOSIS USING UNIVERSAL TUMOR ASSOCIATED ANTIGENS, INCLUDING hTERT
GB9824306D0 (en) 1998-11-05 1998-12-30 Isis Innovation Method for producing dendritic dells
CA2368967A1 (en) * 1999-04-09 2000-10-19 Biomira, Inc. Telomerase-specific cancer vaccine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU781376B2 (en) * 1999-04-09 2005-05-19 Biomira Inc. Telomerase-specific cancer vaccine

Also Published As

Publication number Publication date
EP1068296A1 (en) 2001-01-17
US6440735B1 (en) 2002-08-27
JP2006020648A (ja) 2006-01-26
WO1999050392A1 (en) 1999-10-07
JP2007137889A (ja) 2007-06-07
EP1068296B1 (en) 2011-08-10
CA2347067A1 (en) 1999-10-07
JP2002509716A (ja) 2002-04-02
CA2347067C (en) 2013-09-17
EP1068296A4 (en) 2003-06-04

Similar Documents

Publication Publication Date Title
AU2001255196A1 (en) Compositions and methods for enhancing immunogenicity of antigens
AU634518B2 (en) Hepatitis B core antigen conjugates
IL122340A0 (en) Helicobacter pylori antigens and vaccine compositions
AU2230199A (en) Vaccine compositions and methods of modulating immune responses
AU3760100A (en) Immunostimulatory nucleic acids and antigens
IL145891A0 (en) Methods and compositions for modulating an immune response
EP1068296A4 (en) METHODS AND COMPOSITIONS TO INITIATE AN IMMUNE RESPONSE TO ANTI-TELOMERASE
AU7983198A (en) Improved methods for inducing an immune response
AU3159499A (en) Antigen preparation and use
AU2247095A (en) Cellular immune response-specific antigens and uses therefor
AU7308200A (en) Novel hev antigenic peptide and methods
CZ20011896A3 (cs) Imunogenní prostředek a protilátka
AU2001266845A1 (en) Modulation of immune response and methods based thereon
AU2001261317A1 (en) Immunostimulant compositions and associated methods
AU7585998A (en) Controlling immune response to specific antigens
AU7358098A (en) Radioisotope concentrator methods and compositions
AU2002248646A1 (en) Compositions and methods for modulating an immune response
GB0008992D0 (en) Eliciting improved immune responses
AU5072501A (en) Helicobacter pylori antigens: fusion of hpaa and hpa44
AU6648498A (en) Methods and compositions using interleukin-13 for enhancing immune responses
AUPP371798A0 (en) Parasite antigens
AU2001236001A1 (en) Immune enhancement compositions and use thereof
HK1034462A (en) Compositions and methods of modulating an immune response to an antigen
AU5280901A (en) Helicobacter pylori antigens: fusion of fay 31 and hpa 44
AU2002228729A1 (en) Methods and compositions for inducing an immune response to an antigen

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase